Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 27, Issue 5, 2001, Pages 426-431

  Núñez, Marina ^a   Lana, Raquel ^a   Mendoza, Juan Luis ^a   Martín Carbonero, Luz ^a   Soriano, Vincent ^a,b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Center for Human Evolution and Behavior   (Spain)

Author keywords

Antiretroviral therapy; HAART; Hepatitis C virus; HIV; Liver toxicity

Indexed keywords

AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE;

ADULT; AGE; AGED; ALCOHOL ABUSE; ARTICLE; FEMALE; HEPATITIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER INJURY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SEROLOGY;

EID: 0035881188     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200108150-00002     Document Type: Article

References (27)

1. Severe hepatitis in three AIDS patients treated with indinavir
2. Hepatotoxicity after introduction of highly active antiretroviral therapy
3. Severe hepatic cytolysis: Incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998
4. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection
5. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection
6. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in HIV-infected patients
7. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy
8. Nevirapine: A review of its development, pharmacological profile and potential for clinical use
9. Efavirenz: Shifting the HAART paradigm in adult HIV-1 infection
10. Recurrent NNRTI-induced hepatotoxicity in an HIV-HCV coinfected patient
11. Hepatic safety with nevirapine and two nucleosides in patients with advanced HIV infection, from a placebo-controlled clinical endpoint trial
12. Nevirapine-induced liver toxicity: A prospective cohort study
13. Severe liver toxicity in patients receiving two nucleoside analogues and a nonnucleoside reverse transcriptase inhibitor
14. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men
15. Efficacy of antiretroviral therapy in patients with HIV infection: Study of 807 patients
16. Incidence and factors associated with the occurrence of severe hepatic cytolysis in the ICONA study
17. Chronic hepatitis C in HIV-infected individuals
18. Interferon plus ribavirin in HIV-infected patients with chronic hepatitis C
19. Efficacy and safety of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients
20. Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment
21. Efficacy of interferon plus ribavirin combination treatment and impact of HIV infection in hemophiliacs with chronic hepatitis C and under HAART
22. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with protease inhibitors: An immune restoration disease?
23. Change in transaminases in hepatitis C virus- and HIV-coinfected patients after highly active antiretroviral therapy: Differences between complete and partial virologic responders?
24. Fulminant hepatic failure associated with 2′,3′-dideoxyinosine (ddI)
25. Hepatomegaly with severe steatosisin HIV-seropositive patients
26. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy